» Articles » PMID: 34903128

Effect of MiRNA-200a on Radiosensitivity of Osteosarcoma Cells by Targeting Bone Morphogenetic Protein Receptor 2

Overview
Journal Bioengineered
Date 2021 Dec 14
PMID 34903128
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

To study the effect of miR-200a on radiosensitivity of osteosarcoma cells and its mechanism. NC (normal cell) group, mimic-NC group, mimic-miR-200a group, inhibitor-NC group, inhibitor-miR-200a group, si-NC group, si-BMPR2 (Bone morphogenetic protein receptor 2) group, mimic-miR-200a+vector-NC group, and mimic-miR-200a+vector-BMPR2 group were set; the cells of the above groups were irradiated with different radiation intensities (0, 1, 2, 3, and 4 Gy). The expression of miR-200a and BMPR2 mRNA was detected by qRT-PCR; the expression of BMPR2 protein was detected by Western blot; cell viability was detected by MMT (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide); apoptosis rate was detected by flow cytometry. Cell clone formation experiment was used to detect cell radiosensitivity. Dual-luciferase reporter gene test was used to detect cell fluorescence activity. The expression of BMPR2 was high and the expression of miR-200a was low in osteosarcoma tissues after radiotherapy and in osteosarcoma cells after irradiation. Overexpression of miR-200a and interference with BMPR2 expression inhibits osteosarcoma cell proliferation, promotes apoptosis, and increases cellular radiosensitivity, miR-200a targets expression of BMPR2, and overexpression of BMPR2 reverses the radiosensitizing and apoptotic effects of miR-200a expression on osteosarcoma cells. Overexpression of miR-200a inhibits osteosarcoma cell proliferation, promotes apoptosis, and increases cellular radiosensitivity. The mechanism may be related to the regulation of BMPR2, which may provide new targets and new ideas for osteosarcoma treatment.

Citing Articles

LncRNA EBLN3P attributes methotrexate resistance in osteosarcoma cells through miR-200a-3p/O-GlcNAc transferase pathway.

Sun M, An H, Sun Y, Sun Y, Bai B J Orthop Surg Res. 2022; 17(1):557.

PMID: 36544170 PMC: 9773527. DOI: 10.1186/s13018-022-03449-y.


Functions of the bone morphogenetic protein signaling pathway through non-coding RNAs.

Mukhametov U, Lyulin S, Borzunov D, Sufianova G, Shumadalova A, Zhang D Noncoding RNA Res. 2022; 7(3):178-183.

PMID: 35892126 PMC: 9287601. DOI: 10.1016/j.ncrna.2022.07.002.


MicroRNA miR-331-3p suppresses osteosarcoma progression via the Bcl-2/Bax and Wnt/β-Catenin signaling pathways and the epithelial-mesenchymal transition by targeting N-acetylglucosaminyltransferase I (MGAT1).

Bi W, Yang M, Xing P, Huang T Bioengineered. 2022; 13(6):14159-14174.

PMID: 35758024 PMC: 9342255. DOI: 10.1080/21655979.2022.2083855.


Circular RNA (circ)_0129047 upregulates bone morphogenetic protein receptor type 2 expression to inhibit lung adenocarcinoma progression by sponging microRNA (miR)-1206.

Xue X, Chen Y Bioengineered. 2022; 13(5):12067-12087.

PMID: 35570745 PMC: 9275972. DOI: 10.1080/21655979.2022.2070580.


Hox transcript antisense RNA knockdown inhibits osteosarcoma progression by regulating the phosphoinositide 3-kinase/AKT pathway through the microRNA miR-6888-3p/spleen tyrosine kinase axis.

Wu W, Wang L, Li S Bioengineered. 2022; 13(4):9397-9410.

PMID: 35435107 PMC: 9161905. DOI: 10.1080/21655979.2022.2059614.


References
1.
Reda El Sayed S, Cristante J, Guyon L, Denis J, Chabre O, Cherradi N . MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers (Basel). 2021; 13(11). PMC: 8198729. DOI: 10.3390/cancers13112680. View

2.
Beillard E, Ong S, Giannakakis A, Guccione E, Vardy L, Voorhoeve P . miR-Sens--a retroviral dual-luciferase reporter to detect microRNA activity in primary cells. RNA. 2012; 18(5):1091-100. PMC: 3334695. DOI: 10.1261/rna.031831.111. View

3.
Hiepen C, Jatzlau J, Hildebrandt S, Kampfrath B, Goktas M, Murgai A . BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFβ responses and altered cell mechanics. PLoS Biol. 2019; 17(12):e3000557. PMC: 6927666. DOI: 10.1371/journal.pbio.3000557. View

4.
Cortez M, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin G . Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014; 22(8):1494-1503. PMC: 4435581. DOI: 10.1038/mt.2014.79. View

5.
Owens P, Pickup M, Novitskiy S, Chytil A, Gorska A, Aakre M . Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci U S A. 2011; 109(8):2814-9. PMC: 3286911. DOI: 10.1073/pnas.1101139108. View